2022-05-10T14:35:30-05:00 2021-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2021-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2022-05-10 1 TIMOTHY ARMOUR 999009999 SANDY ROSS P01399337 4012742001 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON ST 310 WELLESLEY HILLS MA 02481 28717249 0 X HTTP://CUREALZ.ORG/ X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. 7 6 26 35 0 0 22874388 26547838 0 0 24835 32050 0 -7161 22899223 26572727 14050077 17719354 0 0 2410583 3128684 0 0 1473932 4545719 2317237 21006379 23165275 1892844 3407452 16427042 23967152 1631589 5766651 14795453 18200501 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 17719354 17719354 IN 2021, CURE ALZHEIMER'S FUND SUPPORTED 77 RESEARCH PROJECTS AT 39 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF MORE THAN $17 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF THE BRAIN'S INNATE IMMUNE SYSTEM AND THE CONTROL OF THE ENTRY AND EXIT OF MATERIALS FOR HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. 2962292 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 20681646 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 21 0 1 26 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812383800 34 WASHINGTON STREET STE 310 WELLESLEY HILLS MA 02481 TIMOTHY ARMOUR PRESIDENT & CEO 40.00 X X 277005 0 9315 BARBARA CHAMBERS EVP MARKETING & COMM. 40.00 X 204402 0 17701 KATHARINE HERMAN EVP DEVELOPMENT 40.00 X 408231 0 28438 JOHN SLATTERY SVP MAJOR GIFTS 40.00 X 185684 0 6433 MARGARET SMITH EVP, RESEARCH ADMIN 30.00 X 206085 0 21067 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 40.00 X 165782 0 20687 KELLY WESTERHOUSE VP GIVING 40.00 X 139693 0 9029 LISA RAND VP MARKETING & COMM. 40.00 X 133345 0 10672 LAUREL LYLE SECRETARY & VP BOARD RELATIONS AND DEVELOPMENT 40.00 X X 104895 0 3682 JEFFREY MORBY CO-CHAIRMAN 20.00 X X 0 0 0 HENRY MCCANCE CO-CHAIRMAN 5.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 1825122 0 127024 9 0 1 0 GRYPHON CONSULTING INC 21 DEAN ST BELMONT MA 02478 FINANCIAL & MGT CONSULTANT 190775 PEARL STREET COLLECTIVE LLC 145 CHADWICK STREET NORTH ANDOVER MA 01845 RECRUITING EXPENSES 131847 PROPER VILLIANS INC 2 SEAPORT LANE 7TH FLOOR BOSTON MA 02210 CREATIVE AND PRODUCTION SERVICES 121411 JOANNE RENCHER & ASSOCIATES LLC 1 BRIARWOOD COURT WARWICK NY 10990 HR SERVICES 102500 4 253982 26293856 5208766 26547838 4497 4497 2093774 2066221 27553 27553 27553 71140 253982 78301 -7161 -7161 26572727 0 0 24889 16141813 16141813 1577541 1577541 1472939 994241 285627 193071 1289329 555739 98372 635218 43271 18728 3565 20978 105847 48171 13937 43739 217298 135775 25097 56426 35656 27644 7560 452 192212 192212 72000 72000 40 40 527249 183341 201492 142416 782714 732534 50180 183549 43150 51027 89372 80543 8689 71854 182873 102240 24888 55745 7292 1286 2027 3979 38976 15590 23386 8433 8433 15299 4136 11163 GIFT PROCESSING FEES 143594 97 143497 MISCELLANEOUS 46807 19028 12306 15473 23165275 20681646 1009697 1473932 6191794 4850918 207998 4457855 3593695 1496905 55727 160657 54458 47509 15382 6949 6362446 12993868 16427042 23967152 959088 430625 5103487 500000 0 172501 232539 1631589 5766651 X 10674191 16316372 4121262 1884129 14795453 18200501 16427042 23967152 3407452 -2404 0 X 0 1 X 1 0 X 17501551 19798072 30497342 22873948 26576211 117247124 17501551 19798072 30497342 22873948 26576211 117247124 15353332 101893792 13021 77320 83306 15472 4497 193616 3644 3644 117444384 24340 0.86760 0.87800 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 72000 0 0 72000 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 54458 47509 6949 6949 ACCRUED PAYROLL AND RELATED 232539 232539 X 26570283 -2404 -2404 26572687 40 40 26572727 23165235 0 23165235 40 40 23165275 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE ORGANIZATION ANNUALY FILES IRS FORM 990- RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGESS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 1098566 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 249550 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 229425 0 0 0 0 0 0 1577541 0 1577541 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SIGNALING FUNCTION OF TREM2 CLEAVAGE PRODUCTS, WHICH ARE AFFECTED BY AGONISTIC ANTIBODIES TO THE STALK REGION 172500 ACH 0 NORTH AMERICA APOE CONSORTIUM: TOWARD DEVELOPING HIGH DENSITY LIPOPROTEIN ENRICHED IN APOLIPOPROTEIN E AS A POTENTIAL BIOMARKER AND THERAPEUTIC TARGETING VASCULAR CONTRIBUTIONS TO ALZHEIMER'S DISEASE 249550 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM TARGETING TAUOPATHIES WITH ANTISENSE OLIGONUCLEOTIDES TO SYNAPTOGYRIN-3 129375 ACH 0 MIDDLE EAST AND NORTH AFRICA "UNDERSTANDING THE MECHANISM UNDERLYING VACCINATION FOR ALZHEIMER'S DISEASE" 229425 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION 67500 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION 105000 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) INFLUENCE OF PLAQUE VICINITY ON MICROGLIAL AND ASTROCYTE GENE EXPRESSION; ROLE OF HUMAN TAU AND TREM2 172289 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMER'S DISEASE: ROLE OF THE CHOROID PLEXUS 34500 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) CIRCUITS: CHARACTERIZING EPIGENETIC BIOMARKERS OF HUMAN COGNITIVE AGING 245350 ACH 0 EUROPE (INCLUDING ICELAND & GREENLAND) TO ACCRUE FOR APPROVED GRANT TO BE FUNDED IN MAY, 2022 172052 ACH 0 10 0 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. PART III ACCOUNTING METHOD: FISHER ISLAND GOLF 325122 253982 71140 47471 4749 26081 325122 253982 71140 47471 4749 26081 78301 -7161 1 AMYLYX 43 THORNDIKE ST CAMBRIDGE MA 02141 464600503 78234 0 PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMER'S DISEASE BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 249026 0 CIRCUITS: A UNIFIED APPROACH TO ACTIONABLE ALZHEIMER'S DISEASE SIGNATURES BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 172500 0 THE ROLE OF MGND-NEURODEGENERATIVE CLEC7A+ MICROGLIA IN AN AD MOUSE MODEL BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 172500 0 TARGETING THE MICROBIOME AND INNATE IMMUNITY BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 250000 0 APOE CONSORTIUM: THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 178612 0 IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501 (C)(3) 172500 0 ROLE OF CHECKPOINT MOLECULE TIM-3 IN REGULATING MICROGLIA IN ALZHEIMER'S DISEASE BOSTON CHILDRENS HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501 (C)(3) 138000 0 NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMER'S DISEASE: ROLE OF THE CHOROID PLEXUS HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501 (C)(3) 244496 0 ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 200000 0 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 25000 0 SUPPLEMENT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI BOX 1049 GUSTAVE L LEVY PLACE NEW YORK NY 10026 136171197 501 (C)(3) 172500 0 ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI BOX 1049 GUSTAVE L LEVY PLACE NEW YORK NY 10026 136171197 501 (C)(3) 172500 0 INVESTIGATING BONE MARROW HEMATOPOIESIS AS THE LINK BETWEEN SLEEP FRAGMENTATION AND VASCULAR INFLAMMATION IN AD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI BOX 1049 GUSTAVE L LEVY PLACE NEW YORK NY 10026 136171197 501 (C)(3) 172500 0 SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION. MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 170907 0 EFFECTS OF CEREBROVASCULAR INSUFFICIENCY AND EXERCISE ON THE AD BRAIN VASCULOMA MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMANNEURAL CULTURE SYSTEMS YR 1 OF 2 MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 115000 0 (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 G2T, AD4, ACTFAST AND GENERAL SCIENTIFIC SUPPORT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 250000 0 CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 58090 0 HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 25000 0 MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR AD MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 300000 0 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 172500 0 TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 041564655 501 (C)(3) 1495000 0 THE CURE ALZ ALZHEIMER'S GENOME PROJECT MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 0 THE ROLE OF CLUSTERIN IN TAU PATHOLOGY MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 0 PATIENT-BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES (YEAR 2) MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 172500 0 HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION MAYO CLINIC 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 250000 0 APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 0 ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD S JACKSONVILLE FL 32224 593337028 501 (C)(3) 172500 0 TARGETING MICROGLIAL TSG 101 FOR SYNAPTIC PROTECTION AND COGNITIVE ENHANCEMENT IN ALZHEIMER'S DISEASE NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVE R607 NEW YORK NY 10016 135562308 501 (C)(3) 174754 0 THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN AD NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 1ST AVE R607 NEW YORK NY 10016 135562308 501 (C)(3) 250000 0 NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTION THE BROAD INSTITUTE INC 415 MAIN ST CAMBRIDGE MA 02142 263428781 501 (C)(3) 172500 0 REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMER'S DISEASE THE BROAD INSTITUTE INC 415 MAIN ST CAMBRIDGE MA 02142 263428781 501 (C)(3) 550000 0 CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501 (C)(3) 172500 0 APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 172500 0 THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 115000 0 CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 250000 0 APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 172500 0 ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 02115 042103547 501 (C)(3) 25000 0 BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 172500 0 BRAIN ENTRY & EXIT CONSORTIUM: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 172500 0 FUNCTIONAL BASIS FOR NOVEL PKC, K56R MUTATION IN ALZHEIMER'S DISEASE THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 291374 0 CONTINUING STUDIES OF THE EFFECTS OF GSM 776890 ADMINISTRATION ON AMYLOID SPECIES AND MICROGLIOSIS IN OLDER ALZHEIMER'S MODEL MICE THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN RIVE LA JOLLA CA 92093 952872494 501 (C)(3) 172500 0 THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 191008 0 PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 257679 0 AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 172500 0 AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES UNIVERSITY OF SOUTHERN CALIFORNIA UNIVERSITY PARK LOS ANGELES CA 90089 951642394 501 (C)(3) 250000 0 CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PATHOLOGY UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 752556007 501 (C)(3) 250000 0 MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE UNIVERSITY OF VIRGINIA 1001 EMMET ST N CHARLOTTESVILLE VA 22903 546001796 501 (C)(3) 172500 0 TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMER'S DISEASE UNIVERSITY OF VIRGINIA 1001 EMMET ST N CHARLOTTESVILLE VA 22903 546001796 501 (C)(3) 229249 0 ADULT HUMAN INEURONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 250000 0 BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 0 NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMER'S DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 300000 0 APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 0 CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 63112 430653611 501 (C)(3) 172500 0 UNDERSTANDING THE ROLE OF NATURAL AB-SPECIFIC B CELL RESPONSES IN AD PROGRESSION WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 172500 0 BRAIN ENTRY AND EXIT CONSORTIUM: LYMPHATICS AND CNS FLUID HOMEOSTASIS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 250000 0 DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1167 YORK AVE NEW YORK NY 10065 136094042 501 (C)(3) 172500 0 ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMER'S AMYLOID BETA WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 061043412 501 (C)(3) 307500 0 CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 114679 0 2021 BEE: BENVENISTE TANNENBAUM: BRAIN ENTRY & EXIT CONSORTIUM: GLYMPHATIC-LYMPHATIC COUPLING IN ALZHEIMER'S DISEASE YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 060646973 501 (C)(3) 172500 0 THE NEUROPROTECTIVE GLIAL BARRIER: A MULTICELLULAR REACTION WITH THERAPEUTIC POTENTIAL IN AD THE BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON TX 77030 741613878 501 (C)(3) 167920 0 ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMER'S DISEASE CARNEGIE MELLON UNIVERSITY 500 FORBES AVE PITTSBURGH PA 15213 250969449 501 (C)(3) 200000 0 CIRCUITS: INTERPRETING ALZHEIMER'S DISEASEASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS MASSACHUSETTS INSTITUTE OF TECHONOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103597 501 (C)(3) 100000 0 (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE MEMORIAL SLOAN KETTERING CANCER 1250 1ST AVE NEW YORK NY 10065 131924236 501 (C)(3) 172500 0 THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON IL 60208 362167817 501 (C)(3) 164314 0 INTERROGATING LEVETIRACETAM'S IMPACT ON AMYLOID PATHOLOGY AND PRESYNAPTIC PROTEOSTASIS IN KNOCK-IN MOUSE MODELS WITH HUMANIZED ABETA NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON IL 60208 362167817 501 (C)(3) 172500 0 T CELL EPIGENETICS IN ALZHEIMER'S DISEASE STONYBROOK UNIVERSITY 100 NICILSS RD STONEY BOOK NY 11794 161514621 501 (C)(3) 50051 0 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES THE BRAIN DONOR PROJECT PO BOX 111002 NAPLES FL 34108 812333601 501 (C)(3) 35050 0 TARGET RECRUITMENT OF UNDERREPRESENTED AMERICANS FOR BRAIN DONOR REGISTRATION UNVERSITY OF KENTUCKY 301 PETERSON SERVICE BLDG LEXINGTON KY 40506 616001218 501 (C)(3) 172500 0 APOLIPOPROTEIN E AND IMMUNOMETABOLISM IN ALZHEIMER'S DISEASE 30 1 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROPOSAL FOR FIT WITH THE CURE ALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A THREE-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X 0 0 0 0 0 0 0 0 0 TIMOTHY ARMOUR PRESIDENT & CEO 277005 0 0 0 0 0 9315 0 0 0 286320 0 0 0 BARBARA CHAMBERS EVP MARKETING & COMM. 204402 0 0 0 0 0 7410 0 10291 0 222103 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 408231 0 0 0 0 0 13395 0 15043 0 436669 0 0 0 JOHN SLATTERY SVP MAJOR GIFTS 185684 0 0 0 0 0 6433 0 0 0 192117 0 0 0 MARGARET SMITH EVP, RESEARCH ADMIN 206085 0 0 0 0 0 7528 0 13539 0 227152 0 0 0 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 165782 0 0 0 0 0 6121 0 14566 0 186469 0 0 0 PROPER VILLIANS INC A PRINCIPAL OF THE VENDOR IS THE SPOUSE OF A KEY EMPLOYEE 121411 CREATIVE AND PRODUCTION SERVICES 0 X 97 5161866 SALE PRICE X AUCTION ITEMS 0 46800 DONOR STATED VALUE 0 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH FIRST REPUBLIC BANK AND BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE PRESIDENT AND CONTRACT CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYERS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.